Celldex Therapeutics, Inc.'s Most Important Takeaway From Q3 Isn't a Number
Investors view quarterly updates from clinical-stage biotechs in a very different way than they do for other companies. The bottom line isn't nearly as important for these small biotechs as are pipeline progress and cash position.
That was certainly the case for Celldex Therapeutics (NASDAQ: CLDX) when it announced second-quarter results in August. And it's still true now, with Celldex reporting its third-quarter results before the market opened on Tuesday. Here are the highlights.
Image source: Getty Images.
Source: Fool.com
Celldex Therapeutics Aktie
37,80 €
-1,05 %
Positive Community-Reaktionen für Celldex Therapeutics mit mehreren Buy-Einschätzungen, keine Sell-Einschätzungen.
Das Community-Kursziel von 62 € für Celldex Therapeutics deutet auf eine deutliche Steigerung um mehr als 50% gegenüber dem aktuellen Kurs von 37.8 € hin.
